Patents by Inventor Robert M. Chanock

Robert M. Chanock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus
    Patent number: 11400150
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines,
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: August 2, 2022
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Government of the United States, as Represented by The Secretary of The Army
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
  • CONSTRUCTION OF WEST NILE VIRUS AND DENGUE VIRUS CHIMERAS FOR USE IN A LIVE VIRUS VACCINE TO PREVENT DISEASE CAUSED BY WEST NILE VIRUS
    Publication number: 20210069317
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines,
    Type: Application
    Filed: November 19, 2020
    Publication date: March 11, 2021
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, The Government of the United States, as Represented by The Secretary of The Army
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
  • Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus
    Patent number: 10869920
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: December 22, 2020
    Assignees: The United States of America, as represented by The Secretary, Department of Health and Human Services, The Government of the United States, as represented by The Secretary of The Army
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
  • CONSTRUCTION OF WEST NILE VIRUS AND DENGUE VIRUS CHIMERAS FOR USE IN A LIVE VIRUS VACCINE TO PREVENT DISEASE CAUSED BY WEST NILE VIRUS
    Publication number: 20200030435
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.
    Type: Application
    Filed: October 8, 2019
    Publication date: January 30, 2020
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, The Government of the United States, as Represented by The Secretary of The Army
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
  • Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus
    Patent number: 10456461
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: October 29, 2019
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Government of the United States, as represented by the Secretary of The Army
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
  • CONSTRUCTION OF WEST NILE VIRUS AND DENGUE VIRUS CHIMERAS FOR USE IN A LIVE VIRUS VACCINE TO PREVENT DISEASE CAUSED BY WEST NILE VIRUS
    Publication number: 20180369358
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.
    Type: Application
    Filed: July 2, 2018
    Publication date: December 27, 2018
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, The Government of the United States, as Represented by The Secretary of The Army
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
  • Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus
    Patent number: 10058602
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: August 28, 2018
    Assignees: The United States of America, as represented by the Secretary, Department of Health & Human Services, The Walter Reed Army Institute of Research
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
  • CONSTRUCTION OF WEST NILE VIRUS AND DENGUE VIRUS CHIMERAS FOR USE IN A LIVE VIRUS VACCINE TO PREVENT DISEASE CAUSED BY WEST NILE VIRUS
    Publication number: 20140294892
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 2, 2014
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
  • Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus
    Patent number: 8778671
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.
    Type: Grant
    Filed: June 18, 2004
    Date of Patent: July 15, 2014
    Assignees: The United States of America, as represented by the Secretary of the Department of Health & Human Services, The Walter Reed Army Institute of Research
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney, Jr.
  • Neutralizing monoclonal antibodies to respiratory syncytial virus
    Patent number: 8221759
    Abstract: The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: July 17, 2012
    Assignee: Intracel Resources LLC
    Inventors: Glenn R. Pilkington, Page S. Gilmour, Robert M. Chanock, James E. Crowe, Jr., Brian R. Murphy
  • Hexavalent bovine rotavirus reassortant composition designed for use in developing countries
    Patent number: 8168202
    Abstract: The present invention provides vaccine compositions for protection against human rotaviral disease designed for use in particular areas of the world. Human× bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined with other VP7 serotypes typically found in the area of interest into a multivalent formulation which provides a high degree of infectivity and immunogenicity. Methods and an administration protocol for producing an immunogenic response without producing an increased risk of intussusception are also provided.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: May 1, 2012
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Albert Z. Kapikian, Lone Simonsen, Timo Vesikari, Yasutaka Hoshino, David M. Morens, Robert M. Chanock, John R. La Montagne, Mary Elaine La Montagne, legal representative, Brian R. Murphy
  • NEUTRALIZING MONOCLONAL ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS
    Publication number: 20120087909
    Abstract: The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention.
    Type: Application
    Filed: September 30, 2011
    Publication date: April 12, 2012
    Inventors: Glenn R. Pilkington, Page S. Gilmour, Robert M. Chanock, James E. Crowe, JR., Brian R. Murphy
  • Multivalent human-bovine rotavirus vaccine
    Patent number: 7932074
    Abstract: The present invention provides vaccine compositions for protection against human rotaviral disease without significant reactogenicity. Human×bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined in a multivalent formulation which provides a high degree of infectivity and immunogenicity without producing a transient febrile condition. Methods for producing an immunogenic response without producing a transient febrile condition are also provided.
    Type: Grant
    Filed: July 27, 1999
    Date of Patent: April 26, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Albert Z. Kapikian, Robert M. Chanock, Yasutaka Hoshino
  • Neutralizing monoclonal antibodies to respiratory syncytial virus
    Publication number: 20090110684
    Abstract: The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention.
    Type: Application
    Filed: April 24, 2008
    Publication date: April 30, 2009
    Inventors: Glenn R. Pilkington, Page S. Gilmour, Robert M. Chanock, James E. Crowe, JR., Brian R. Murphy
  • Neutralizing monoclonal antibodies to respiratory syncytial virus
    Patent number: 7488477
    Abstract: The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention.
    Type: Grant
    Filed: April 30, 2003
    Date of Patent: February 10, 2009
    Assignee: Intracel Resources LLC
    Inventors: Glenn R. Pilkington, Page S. Gilmour, Robert M. Chanock, James E. Crowe, Jr., Brian R. Murphy
  • Hexavalent Bovine Rotavirus Reassortant Composition Designed for Use in Developing Countries
    Publication number: 20080292660
    Abstract: The present invention provides vaccine compositions for protection against human rotaviral disease designed for use in particular areas of the world. Human×bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined with other VP7 serotypes typically found in the area of interest into a multivalent formulation which provides a high degree of infectivity and immunogenicity. Methods and an administration protocol for producing an immunogenic response without producing an increased risk of intussusception are also provided.
    Type: Application
    Filed: July 7, 2006
    Publication date: November 27, 2008
    Inventors: Albert Z. Kapikian, Lone Simonsen, Timo Vesikari, Yasutaka Hoshino, David M. Morens, Robert M. Chanock, John R. La Montagne, Brian R. Murphy
  • Human neutralizing monoclonal antibodies to respiratory syncytial virus
    Patent number: 7364737
    Abstract: Human monoclonal antibodies and fragments thereof which bind, neutralize and provide passive immunotherapy to respiratory syncytial virus (RSV) antigenic subgroups A and B are disclosed. Also disclosed are diagnostic and immunotherapeutic methods of using the monoclonal antibodies as well as cell line producing the monoclonal antibodies.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: April 29, 2008
    Assignee: The Scripps Research Institute
    Inventors: Dennis R. Burton, Carlos F. Barbas, III, Robert M. Chanock, Brian R. Murphy, James E. Crowe, Jr.
  • Attenuated human rotavirus vaccine
    Patent number: 7150984
    Abstract: The present invention provides vaccine compositions of attenuated human rotavirus. More particularly, the attenuated human rotavirus is produced by cold passage and thus contains attenuating mutations which produce virus having a cold-adapted (ca) and temperature sensitive (ts) phenotype. The attenuated strains are used in methods for stimulating the immune system of an individual to induce protection against human rotavirus by administration of the ca attenuated rotavirus.
    Type: Grant
    Filed: July 11, 1995
    Date of Patent: December 19, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Yasutaka Hoshino, Albert Z. Kapikian, Robert M. Chanock
  • Human neutralizing monoclonal antibodies to respiratory syncytial virus
    Publication number: 20040234528
    Abstract: Human monoclonal antibodies and fragments thereof which bind and neutralize respiratory syncytial virus (RSV) antigenic subgroups A and B are disclosed. Also disclosed are diagnostic and immunotherapeutic methods of using the monoclonal antibodies as well as cell lines producing the monoclonal antibodies.
    Type: Application
    Filed: January 29, 2004
    Publication date: November 25, 2004
    Applicant: The Scripps Research Institute, a California corporation
    Inventors: Dennis R. Burton, Carlos F. Barbas, Robert M. Chanock, Brian R. Murphy, James E. Crowe
  • Compositions and method for preventing reactogenicity associated with administration of immunogenic live rotavirus compositions
    Publication number: 20040223981
    Abstract: The present invention provides compositions for making a medicament and methods for the administration of a vaccine compositions for protection against human rotaviral disease without significant reactogenicity. Human×rhesus reassortant rotavirus compositions were made which when were administered during the first 7 to about 10 days of life, provided a composition which was non-reactogenic followed by booster immunizations at 16 to 18 weeks or 14 to 20 weeks, up to 1 year of age. The immune response induced by the initial neonatal administration of the live rotavirus vaccine composition protects the infant from the reactogenicity of the composition when administered as a second dose at or after 2 months of age. Administration of thee immunogenic composition also is expected to ablate or significantly diminish the increase in the excess of imussusception observed 3 to 7 days following administration of the initial dose of rotavirus vaccine at about 2 to 4 months.
    Type: Application
    Filed: August 8, 2003
    Publication date: November 11, 2004
    Inventors: Albert Z. Kapikian, Robert M. Chanock, Timo Vesikari